CUHK-developed novel peptide drug candidate granted FDA Orphan Drug Designation Offering new hope for Huntington's disease patients
September 23, 2026
September 23, 2026
SHATIN, Hong Kong, Sept. 23 -- The Chinese University of Hong Kong posted the following news release:
* * *
CUHK-developed novel peptide drug candidate granted FDA Orphan Drug Designation Offering new hope for Huntington's disease patients
*
A novel peptide drug candidate, jointly developed by the School of Life Sciences at The Chinese University of Hong Kong (CUHK) and its biotechnology spin-off company Rare Power Limited, has been grante . . .
* * *
CUHK-developed novel peptide drug candidate granted FDA Orphan Drug Designation Offering new hope for Huntington's disease patients
*
A novel peptide drug candidate, jointly developed by the School of Life Sciences at The Chinese University of Hong Kong (CUHK) and its biotechnology spin-off company Rare Power Limited, has been grante . . .
